Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 141

1.

Scaffold-fused riboregulators for enhanced gene activation in Synechocystis sp. PCC 6803.

Sakai Y, Abe K, Nakashima S, Ellinger JJ, Ferri S, Sode K, Ikebukuro K.

Microbiologyopen. 2015 Apr 10. doi: 10.1002/mbo3.257. [Epub ahead of print]

2.

Epigenetic biomarkers in the blood of patients with urological malignancies.

Ellinger J, Müller SC, Dietrich D.

Expert Rev Mol Diagn. 2015 Apr;15(4):505-16. doi: 10.1586/14737159.2015.1019477. Epub 2015 Feb 26.

PMID:
25719388
3.

Identification of novel long non-coding RNAs in clear cell renal cell carcinoma.

Blondeau JJ, Deng M, Syring I, Schrödter S, Schmidt D, Perner S, Müller SC, Ellinger J.

Clin Epigenetics. 2015 Feb 8;7(1):10. doi: 10.1186/s13148-015-0047-7. eCollection 2015.

4.

Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer.

Kriebel S, Schmidt D, Holdenrieder S, Goltz D, Kristiansen G, Moritz R, Fisang C, Müller SC, Ellinger J.

PLoS One. 2015 Jan 28;10(1):e0117284. doi: 10.1371/journal.pone.0117284. eCollection 2015.

5.

Prostaglandin receptors EP1-4 as a potential marker for clinical outcome in urothelial bladder cancer.

von der Emde L, Goltz D, Latz S, Müller SC, Kristiansen G, Ellinger J, Syring I.

Am J Cancer Res. 2014 Nov 19;4(6):952-62. eCollection 2014.

6.

[Detection of cell-free lncRNA in serum of cancer patients.]

Kohls K, Schmidt D, Holdenrieder S, Müller SC, Ellinger J.

Urologe A. 2014 Oct 15. [Epub ahead of print] German.

PMID:
25312755
7.

Ischämischer Priapismus--Erfolg der T-Shunt-Anlage.

Ellinger J, Müller SC.

Aktuelle Urol. 2014 Jul;45(4):259-60. doi: 10.1055/s-0034-1389225. Epub 2014 Aug 28. German. No abstract available.

PMID:
25166600
8.

Evidence from the 'PROspective MulticEnTer RadIcal Cystectomy Series 2011 (PROMETRICS 2011)' study: how are preoperative patient characteristics associated with urinary diversion type after radical cystectomy for bladder cancer?

Schmid M, Rink M, Traumann M, Bastian PJ, Bartsch G, Ellinger J, Grimm MO, Hadaschik B, Haferkamp A, Hakenberg OW, Aziz A, Hartmann F, Herrmann E, Hohenfellner M, Janetschek G, Gierth M, Pahernik Sh, Protzel C, Roigas J, Gördük M, Lusuardi L, May M, Trinh QD, Fisch M, Chun FK; PROMETRICS 2011 Research Group.

Ann Surg Oncol. 2015 Mar;22(3):1032-42. doi: 10.1245/s10434-014-4029-3. Epub 2014 Aug 28.

PMID:
25164037
9.

Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.

Syring I, Bartels J, Holdenrieder S, Kristiansen G, Müller SC, Ellinger J.

J Urol. 2015 Jan;193(1):331-7. doi: 10.1016/j.juro.2014.07.010. Epub 2014 Jul 18.

PMID:
25046619
10.

KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy.

Stein J, Majores M, Rohde M, Lim S, Schneider S, Krappe E, Ellinger J, Dietel M, Stephan C, Jung K, Perner S, Kristiansen G, Kirfel J.

Am J Pathol. 2014 Sep;184(9):2430-7. doi: 10.1016/j.ajpath.2014.05.022. Epub 2014 Jul 9.

PMID:
25016185
11.

Analysis of strains lacking known osmolyte accumulation mechanisms reveals contributions of osmolytes and transporters to protection against abiotic stress.

Murdock L, Burke T, Coumoundouros C, Culham DE, Deutch CE, Ellinger J, Kerr CH, Plater SM, To E, Wright G, Wood JM.

Appl Environ Microbiol. 2014 Sep;80(17):5366-78. doi: 10.1128/AEM.01138-14. Epub 2014 Jun 20.

12.

Nucleic acid-based tissue biomarkers of urologic malignancies.

Dietrich D, Meller S, Uhl B, Ralla B, Stephan C, Jung K, Ellinger J, Kristiansen G.

Crit Rev Clin Lab Sci. 2014 Aug;51(4):173-99. doi: 10.3109/10408363.2014.906130. Epub 2014 May 30.

PMID:
24878394
13.

MicroRNAs: a novel non-invasive biomarker for patients with urological malignancies.

Ellinger J, Muller SC.

Curr Pharm Biotechnol. 2014;15(5):486-91.

PMID:
24846060
14.

Alterations of global histone H3K9 and H3K27 methylation levels in bladder cancer.

Ellinger J, Bachmann A, Göke F, Behbahani TE, Baumann C, Heukamp LC, Rogenhofer S, Müller SC.

Urol Int. 2014;93(1):113-8. doi: 10.1159/000355467. Epub 2014 Feb 18.

PMID:
24556868
15.

Serum microRNAs as biomarkers in patients undergoing prostate biopsy: results from a prospective multi-center study.

Westermann AM, Schmidt D, Holdenrieder S, Moritz R, Semjonow A, Schmidt M, Kristiansen G, Müller SC, Ellinger J.

Anticancer Res. 2014 Feb;34(2):665-9.

PMID:
24510997
16.

DNA hypermethylation as a predictor of PSA recurrence in patients with low- and intermediate-grade prostate cancer.

Moritz R, Ellinger J, Nuhn P, Haese A, Müller SC, Graefen M, Schlomm T, Bastian PJ.

Anticancer Res. 2013 Dec;33(12):5249-54.

PMID:
24324057
17.
18.

Databases and Software for NMR-Based Metabolomics.

Ellinger JJ, Chylla RA, Ulrich EL, Markley JL.

Curr Metabolomics. 2013;1(1). doi: 10.2174/2213235X11301010028.

19.

Serum DNA hypermethylation in patients with kidney cancer: results of a prospective study.

Hauser S, Zahalka T, Fechner G, Müller SC, Ellinger J.

Anticancer Res. 2013 Oct;33(10):4651-6.

PMID:
24123044
20.

Prognostic significance of venous tumour thrombus consistency in patients with renal cell carcinoma (RCC).

Weiss VL, Braun M, Perner S, Harz A, Vorreuther R, Kristiansen G, Müller SC, Ellinger J.

BJU Int. 2014 Feb;113(2):209-17. doi: 10.1111/bju.12322. Epub 2013 Dec 2.

PMID:
24053185
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk